Fludeoxyglucose

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Fludeoxyglucose is a radiopharmaceutical indicated for PET scans.

Generic Name
Fludeoxyglucose
DrugBank Accession Number
DB15107
Background

Fludeoxyglucose is under investigation in clinical trial NCT03262389 (Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 182.147
Monoisotopic: 182.059051617
Chemical Formula
C6H11FO5
Synonyms
Not Available

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
ZO2JV75L55
CAS number
29702-43-0
InChI Key
AOYNUTHNTBLRMT-SLPGGIOYSA-N
InChI
InChI=1S/C6H11FO5/c7-3(1-8)5(11)6(12)4(10)2-9/h1,3-6,9-12H,2H2/t3-,4+,5+,6+/m0/s1
IUPAC Name
(2R,3S,4R,5R)-2-fluoro-3,4,5,6-tetrahydroxyhexanal
SMILES
OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O

References

General References
  1. AIFA: Efdege (Fluodeoxyglucose) Injection [Link]
ChemSpider
148702
ChEBI
49135
ChEMBL
CHEMBL1908940
ZINC
ZINC000001846431
Wikipedia
Fluorodeoxyglucose_(18F)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedDiagnosticPositron-Emission Tomography and Cone-Beam Computed Tomography1
4TerminatedBasic ScienceAbdominal Aortic Aneurysms (AAA)1
2CompletedDiagnosticMalignancies1
2CompletedDiagnosticMultiple Myeloma (MM)1
2CompletedTreatmentHippel Lindau Disease / Renal Cancers1
2Not Yet RecruitingDiagnosticDeep Vein Thrombosis / Pulmonary Diseases / Pulmonary Embolism / Respiratory Diseases / Venous Thromboembolism Diseases1
1, 2CompletedDiagnosticAdult Giant Cell Glioblastoma / Advanced Non Small Cell Lung Cancer (NSCLC) / Breast Cancer Stage IIIc / Breast Cancer, Stage IIIB / Carcinoma Breast Stage IV / Glioblastoma, Adult / Gliosarcoma, Adult / Male Breast Cancer / Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Non-small Cell Lung Cancer (NSCLC), Recurrent / Recurrent Adenoid Cystic Carcinoma of the Oral Cavity / Recurrent Basal Cell Carcinoma of the Lip / Recurrent Brain Tumor, Adult / Recurrent Colon Cancer / Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Recurrent Hypopharyngeal Cancer / Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Recurrent Laryngeal Cancer / Recurrent Lip and Oral Cavity Cancer / Recurrent Lymphoepithelioma of the Nasopharynx / Recurrent Lymphoepithelioma of the Oropharynx / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Recurrent Mucoepidermoid Carcinoma of the Oral Cavity / Recurrent Nasopharyngeal Cancer / Recurrent Oropharyngeal Cancer / Recurrent Pancreatic Cancer / Recurrent Paranasal Sinus and Nasal Cavity Cancer / Recurrent Rectal Cancer / Recurrent Salivary Gland Cancer / Renal Cell Cancer, Recurrent / Stage IIIA Breast Cancer / Stage IIIA Non Small Cell Lung Cancer / Stage IIIB Non Small Cell Lung Cancer / Stage IV Pancreatic Cancer / Stage IV Renal Cell Cancer / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVA Salivary Gland Cancer / Stage IVB Colon Cancer / Stage IVB Salivary Gland Cancer / Stage IVC Salivary Gland Cancer / Tongue Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedDiagnosticPulmonary Hypertension (PH)1
0CompletedDiagnosticUnspecified Adult Solid Tumor, Protocol Specific1
Not AvailableWithdrawnNot AvailableThyroid Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionParenteral1 GBq
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility139.0 mg/mLALOGPS
logP-1.8ALOGPS
logP-2.7ChemAxon
logS-0.12ALOGPS
pKa (Strongest Acidic)12.25ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area97.99 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity35.65 m3·mol-1ChemAxon
Polarizability15.52 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 20, 2019 14:50 / Updated on May 14, 2021 01:07